Erratum: Department of Error (The Lancet (2016) 387(10036) (2382)(S0140673616301374) (10.1016/S0140-6736(16)30137-4));Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial

The Lancet

Volumn 387, Issue 10036, 2016, Pages 2412-2421

  Patel, Amit N ^a   Henry, Timothy D ^b   Quyyumi, Arshed A ^c   Schaer, Gary L ^d   Anderson, R David ^e   Toma, Catalin ^f   East, Cara ^g   Remmers, Ann E ^h   Goodrich, James ^h   Desai, Akshay S ⁱ   Recker, David ^h   DeMaria, Anthony ^j  

^a UNIVERSITY OF UTAH   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h Aastrom Biosciences Inc   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IXMYELOCEL T; PLACEBO;

ACUTE HEART FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CELL THERAPY; CHILD; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOCARDIAL INJECTION CATHETER; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; BIOLOGICAL THERAPY; CARDIOMYOPATHY, DILATED; COMPLICATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; MIDDLE AGED; PROCEDURES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; CARDIOMYOPATHY, DILATED; CELL- AND TISSUE-BASED THERAPY; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84962135852     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30739-5     Document Type: Erratum

References (27)

1. 1 Mozaffarian, D, Benjamin, EJ, Go, AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–360.
2. 2 McLaren, DP, Jones, R, Plotnik, R, et al. Prior hospital admission predicts thirty-day hospital readmission for heart failure patients. Cardiol J, 2016, 10.5603/CJ.a2016.0005 published online Jan 18.
3. 3 Chen, J, Normand, SL, Wang, Y, Krumholz, HM, National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 306 (2011), 1669–1678.
4. 4 Chiong, M, Wang, ZV, Pedrozo, Z, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis, 2, 2011, e244.
5. 5 Agnetti, G, Piepoli, MF, Siniscalchi, G, Nicolini, F, New insights in the diagnosis and treatment of heart failure. Biomed Res Int 2015 (2015), 265–360.
6. 6 Kilic, A, Acker, MA, Atluri, P, Dealing with surgical left ventricular assist device complications. J Thorac Dis 7 (2015), 2158–2164.
7. 7 Patel, AN, Silva, F, Winters, AA, Stem cell therapy for heart failure. Heart Fail Clin 11 (2015), 275–286.
8. 8 Patel, AN, Mittal, S, Turan, G, et al. REVIVE Trial: retrograde delivery of autologous bone marrow in patients with heart failure. Stem Cells Transl Med 4 (2015), 1021–1027.
9. 9 Leistner, DM, Schmitt, J, Palm, S, et al. Intracoronary administration of bone marrow-derived mononuclear cells and arrhythmic events in patients with chronic heart failure. Eur Heart J 32 (2011), 485–491.
10. 10 Fisher, SA, Doree, C, Taggart, DP, et al. Cell therapy for heart disease: trial sequential analyses of two cochrane reviews. Clin Pharmacol Ther, 2016, 10.1002/cpt.344 published online Jan 28.
11. 11 Schächinger, V, Erbs, S, Elsässer, A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 (2006), 1210–1221.
12. 12 Assmus, B, Fischer-Rasokat, U, Honold, J, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res 100 (2007), 1234–1241.
13. 13 Perin, EC, Willerson, JT, Pepine, CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 307 (2012), 1717–1726.
14. 14 Ledford, KJ, Murphy, N, Zeigler, F, et al. Therapeutic potential of Ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases. Stem Cell Res Ther, 6, 2015, 25.
15. 15 Bartel, RL, Cramer, C, Ledford, K, et al. The Aastrom experience. Stem Cell Res Ther, 3, 2012, 26.
16. 16 Ledford, KJ, Zeigler, F, Bartel, RL, Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res Ther, 4, 2013, 134.
17. 17 Henry, TD, Traverse, JH, Hamman, BL, et al. Safety and efficacy of Ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 115 (2014), 730–737.
18. 18 Henry, TD, Schaer, G, Demaria, A, et al. The iXCell-DCM trial: rationale and design. Cell Transplant, 2016 published online March 7. http://dx.doi.org/10.3727/096368916X691295.
19. 19 Pocock, SJ, Ariti, CA, Collier, TJ, Wang, D, The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 33 (2012), 176–182.
20. 20 Finkelstein, DM, Schoenfeld, DA, Combining mortality and longitudinal measures in clinical trials. Stat Med 18 (1999), 1341–1354.
21. 21 Kissel, CK, Lehmann, R, Assmus, B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 49 (2007), 2341–2349.
22. 22 Heldman, AW, DiFede, DL, Fishman, JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311 (2014), 62–73.
23. 23 Perin, EC, Borow, KM, Silva, GV, et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res 117 (2015), 576–584.
24. 24 Bolli, R, Chugh, AR, D'Amario, D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378 (2011), 1847–1857.
25. 25 Makkar, RR, Smith, RR, Cheng, K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomized phase 1 trial. Lancet 379 (2012), 895–904.
26. 26 Bartunek, J, Behfar, A, Dolatabadi, D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol, 61, 2013, 232938.
27. 27 FDA Guidance for Industry: Cellular Therapy for Cardiac Disease 2010. http://www.fda.gov/cber/guidelines.htm (accessed April 1, 2016).